Can a lung drug help COVID survivors breathe easier?

NCT ID NCT04619680

First seen May 07, 2026 ยท Last updated May 07, 2026

Summary

This study tested whether the drug nintedanib can slow lung scarring in people who had severe COVID-19 and still have lung problems more than 30 days later. 103 adults across the US took part. The main goal was to see if the drug helped maintain lung function, measured by how much air they could exhale forcefully.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Baylor University Medical Center Dallas

    Dallas, Texas, 75246, United States

  • Emory Healthcare Network

    Atlanta, Georgia, 30322, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Mount Sinai Beth Israel

    New York, New York, 10003, United States

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • University of Utah

    Salt Lake City, Utah, 84108, United States

Conditions

Explore the condition pages connected to this study.